Wockhardt Limited · NSE:WOCKPHARMA

Wockhardt — Q3 FY2014 Earnings Presentation

23 slides from Wockhardt's earnings presentation, February 2014

  1. Slide 1: Wockhardt Limited Investor Presentation

    Slide 1: Wockhardt Limited Investor Presentation

    Wockhardt Limited Investor Presentation By Dr. Murtaza Khorakiwala Managing Director Feb 2014

  2. Slide 2: Safe Harbor Statement

    Slide 2: Safe Harbor Statement

    Safe Harbor Statement • Except for historical information contained herein, statements in this communication, which include words or phrases such as “will”, “aim”, “will likely result”, “would”, “believe”, “may”, “expect”, “will continue”, “anticipate”, “estimate”, “intend”, “plan”, “contemplate”, “

  3. Slide 3: Introduction to Wockhardt

    Slide 3: Introduction to Wockhardt

    Introduction to Wockhardt Key Business Dynamics

  4. Slide 4: Wockhardt Today

    Slide 4: Wockhardt Today

    Wockhardt Today UK, Ireland, France, Switz. USA Direct Operations in India, USA Mexico India and Europe 8600 Associates employed in 21 countries Wockhardt Direct ROW operations operations Investor Presentation Feb 2014 4

  5. Slide 5: Wockhardt Today

    Slide 5: Wockhardt Today

    Wockhardt Today UK Ireland 9 sites Chicago in India 12 Baddi Manufacturing Locations globally Ankleshwar Daman (2 Plants) Aurangabad (5 Plants) Formulations APIs Investor Presentation Feb 2014 5

  6. Slide 6: Wockhardt Today R&D Centers

    Slide 6: Wockhardt Today R&D Centers

    Wockhardt Today 3 R&D Centers worldwide USA / UK & India Investor Presentation Feb 2014 6

  7. Slide 7: Update on Recent Events

    Slide 7: Update on Recent Events

    Update on Recent Events TWOCKHARDT

  8. Slide 8: Regulatory Inspections

    Slide 8: Regulatory Inspections

    Regulatory Inspections TWOCKHARDT

  9. Slide 9: Q3FY14 / 9MFY14 Regulatory Inspection Status

    Slide 9: Q3FY14 / 9MFY14 Regulatory Inspection Status

    Update on Recent Events Q3FY14 / 9MFY14 – Regulatory Inspection Status Q3FY14 9MFY14 Total No. of Regulatory Inspections 6 17 +ve outcomes (with no or minor observations) 5 13 -ve outcomes (with critical / major observations) 1 4 Result Awaited 0 0 Chikalthana facility received an Import Alert from

  10. Slide 10: Q3FY14 Results

    Slide 10: Q3FY14 Results

    Q3FY14 Results TWOCKHARDT

  11. Slide 11: Sales – Decline of 14% over Q3FY13

    Slide 11: Sales – Decline of 14% over Q3FY13

    Sales – Decline of 14% over Q3FY13 Sales 1,500 1,300 1,100 Rs.crore 1,435 900 1,237 700 500 Q3-FY13 Q3-FY14 Decline of 14% in Q3FY14 over Q3FY13 Investor Presentation Feb 2014 11

  12. Slide 12: EBITDA – Declines by 56% over Q3FY13

    Slide 12: EBITDA – Declines by 56% over Q3FY13

    EBITDA – Declines by 56% over Q3FY13 EBITDA 600 500 400 Rs.crore 300 545 200 100 241 0 Q3-FY13 Q3-FY14 Declines by 56% in Q3FY14 over Q3FY13 Investor Presentation Feb 2014 12

  13. Slide 13: Adj. PAT – Declines by 40%

    Slide 13: Adj. PAT – Declines by 40%

    Adj. PAT – Declines by 40% Adj. PAT 500 400 300 Rs.crore 200 410 250 100 0 Q3-FY13 Q3-FY14 Declines by 40% in Q3FY14 over Q3FY13 Investor Presentation Feb 2014 13

  14. Slide 14: Research – 9.2% of Sales

    Slide 14: Research – 9.2% of Sales

    Research – 9.2% of Sales 11.0% R&D % to Sales 10.2% 10.0% 9.2% 9.0% 8.0% 7.7% 7.0% 6.7% 6.0% 5.7% 5.0% 4.0% 3.5% 3.0% 2.0% FY11 FY12 FY13 Q1FY14 Q2FY14 Q3FY14 Investor Presentation Feb 2014 14

  15. Slide 15: 9MFY14 Results

    Slide 15: 9MFY14 Results

    OMFY14 Results TWOCKHARDT

  16. Slide 16: Sales – Decline of 8% over 9MFY13

    Slide 16: Sales – Decline of 8% over 9MFY13

    Sales – Decline of 8% over 9MFY13 Sales 4,500 4,000 3,500 Rs.crore 3,000 4,124 3,792 2,500 2,000 1,500 9M-FY13 9M-FY14 Decline of 8% in 9MFY14 over 9MFY13 Investor Presentation Feb 2014 16

  17. Slide 17: EBITDA – Declines by 43% over 9MFY13

    Slide 17: EBITDA – Declines by 43% over 9MFY13

    EBITDA – Declines by 43% over 9MFY13 EBITDA 1,600 1,400 1,200 1,000 Rs.crore 800 1,504 600 400 858 200 0 9M-FY13 9M-FY14 Declines by 43% in 9MFY14 over 9MFY13 Investor Presentation Feb 2014 17

  18. Slide 18: Adj. PAT – Declines by 40%

    Slide 18: Adj. PAT – Declines by 40%

    Adj. PAT – Declines by 40% Adj. PAT 1,400 1,200 1,000 800 Rs.crore 600 1,180 400 707 200 0 9M-FY13 9M-FY14 Declines by 40% in 9MFY14 over 9MFY13 Investor Presentation Feb 2014 18

  19. Slide 19: Key Financial Highlights

    Slide 19: Key Financial Highlights

    Key Financial Highlights  Net Debt to Equity now at 0.06 as against 0.36 as of 31st Mar 2013.  Free Cash Flow (before Capex) generation of over Rs.1,100 crores in 9MFY14.  Capital Expenditure of Rs.307 crores in 9MFY14.  R&D expenses at 9.2% of sales in Q3FY14 and at 9% of sales in 9MFY14. Inves

  20. Slide 20: US Business

    Slide 20: US Business

    US Business • Declines by 30% (37% in $terms) over Q3FY13. • 7 ANDAs filed during 9MFY14. USA • 53 ANDAs pending approval. 800 $141 700 600 $89 Rs.cr. 500 400 771 539 300 Q3-FY13 Q3-FY14 Investor Presentation Feb 2014 20

  21. Slide 21: EU Operations

    Slide 21: EU Operations

    EU Operations UK Operations 280 UK £ 27.3 260 • UK operation grows by 10% (Flat in £ terms) in Q3FY14. £ 27.4 240 Grows by 5% (remains flat in £ terms) in 9MFY14. 220 • 4 New products launched in 9MFY14. Rs.cr. 200 180 160 • 3 largest generic company and 1st in Hospital segment 140 238 261 120 Q3-FY

  22. Slide 22: Emerging Markets

    Slide 22: Emerging Markets

    Emerging Markets • Emerging Markets (including India) declined by 15% for Q3FY14. Declines by 21% for 9MFY14. • India Business grew by 6% during Q3FY14 • 2 new products in Q3FY14 and 16 new products launched in 9MFY14 in India. Emerging Markets • 2 new divisions launched in India. 350 • ROW operatio

  23. Slide 23: Investor updates and contact information

    Slide 23: Investor updates and contact information

    For investor updates and communication please visit www.wockhardt.com For Information please contact Tushar Mistry Tel.: +91 22 26596210 tmistry@wockhardt.com 23 Investor Presentation Feb 2014

Source: Internet Archive copy of wockhardt.com

More decks from Wockhardt Limited

All 22 Wockhardt decks